PT - JOURNAL ARTICLE AU - Birendra Kumar Sah AU - Benyan Zhang AU - Huan Zhang AU - Jian Li AU - Fei Yuan AU - Tao Ma AU - Min Shi AU - Wei Xu AU - Zhenglun Zhu AU - Wentao Liu AU - Chao Yan AU - Chen Li AU - Bingya Liu AU - Min Yan AU - Zhenggang Zhu TI - Neoadjuvant Docetaxel, Oxaliplatin, Leucovorin, and 5-Fluorouracil (FLOT) Versus S-1 plus Oxaliplatin (SOX) for Patients with Locally Advanced Gastric Cancer AID - 10.1101/2020.06.21.20136887 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.21.20136887 4099 - http://medrxiv.org/content/early/2020/07/02/2020.06.21.20136887.short 4100 - http://medrxiv.org/content/early/2020/07/02/2020.06.21.20136887.full AB - Background Despite growing trends of neoadjuvant chemotherapy for advanced gastric cancer, there is still no consensus of optimal regimens between East and West countries. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, fluorouracil, and Leucovorin (FLOT) regimen has shown promising results in terms of pathological response and survival rate. However, S-1 plus oxaliplatin (SOX) is a more favorable chemotherapy regimen in Eastern countries. We conducted this study to evaluate the safety and efficacy of both regimens, and to explore a suitable regimen for Chinese patients.Methods Patients with locally advanced gastric cancer(LAGC) were 1:1 randomly assigned to receive either 4 cycles of FLOT or 3 cycles of SOX regimen before curative gastrectomy. The primary endpoint was the comparison of complete or sub-total tumor regression grading (TRG1a+ TRG1b) in the primary tumor.Results Altogether 74 cases enrolled between August 2018 and March 2020. All 74 randomly assigned cases were considered as intention-to-treat (ITT) population, and the 55 patients who completed the planned chemotherapy plus surgery were considered as per protocol (PP) population. There was no significant difference in pre-treatment clinicopathological parameters between the FLOT and SOX group(p>0.05). There was no significant difference in adverse effects or postoperative morbidity and mortality between two groups (p>0.05). Similarly, there was no significant difference in the proportion of tumor regression grading between the FLOT and SOX group(p>0.05). In the ITT population, complete or sub-total TRG was 20.0 % in FLOT versus 32.4 % in the SOX group (p>0.05).Conclusions Our study demonstrates that FLOT and SOX regimens are similarly effective for locally advanced gastric cancer patients in terms of clinical downstaging and pathological response. Both regimens were well-tolerated in this study. A large scale phase 3 randomized controlled trial is necessary to validate this result.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov, number NCT03636893Funding StatementThe overall costs of publication will be funded by grants from the National Natural Science Foundation of China (No. 91529302 (BY Liu), No.81772509 (Liu BY), and No. 81871904 (Zhu ZG)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:institutional review board (IRB), Ruijin HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny data regarding this study are kept safe with corresponding authors and can be obtained for reasonable request.